Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors

BACKGROUND: Brain tumors are the leading cause of cancer death for pediatric patients. Pelareorep, an immunomodulatory oncolytic reovirus, has intravenous efficacy in preclinical glioma models when preconditioned with GM-CSF (sargramostim). We report a phase I trial with the primary goal of evaluati...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuelke, Matthew R, Gundelach, Justin H, Coffey, Matt, West, Emma, Scott, Karen, Johnson, Derek R, Samson, Adel, Melcher, Alan, Vile, Richard G, Bram, Richard J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268737/
https://www.ncbi.nlm.nih.gov/pubmed/35821679
http://dx.doi.org/10.1093/noajnl/vdac085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268737/
https://www.ncbi.nlm.nih.gov/pubmed/35821679
http://dx.doi.org/10.1093/noajnl/vdac085

Ejemplares similares